Outsourcing Articles

Biopharmaceutical manufacturing is undergoing a major paradigm change from unique, highly specialized processing of individual products to uniform systematic processing that applies to a multitude of products.

Biopharma CMO Market Report

Optimism is high among bio-contract manufacturers

By William Downey

Wel come to our 4th Annual Contract Pharma Outsourcing Survey! More than 175 sponsor-side respondents offered up their opinions on outsourcing trends for this year's poll. Here's a breakdown of respondents by company type:

* Small/Mid-Tier Pharma - 25.7%
* Big Pharma - 23.6%
* Virtual Pharma - 12.1%
* Generic Pharma - 12.1%
* Emerging Biopharma - 10.0%

n a company receives a warning letter, it is usually an exciting event - in every sense of the word. The letter could show up unexpectedly.

With the rise in outsourcing new drug and biologic development to overseas laboratories, how are biopharmaceutical executives protecting their intellectual property (IP) from insider theft?

he pharmaceutical industry is a $500 billion global business that requires the tightest, safest, and most efficient supply chain possible, to produce the highest quality drugs on time for distribution wherever they are needed. Modern pharmaceutical products rely on ingredients and material from across the globe.

In the pharmaceutical and biotechnology business, the perceived center of the known universe has always been either the East Coast or the West Coast of the U.S. But the future for both industries may be determined not only by global players beyond U.S. borders, but in some other American states in between.

Photo courtesy of Cook Pharmica